SAS Institute Inc. v. Iancu

SAS Institute Inc. v. Iancu

SAS Institute Inc. v. Iancu was a 2018 decision of the Supreme Court of the United States resolving a dispute about procedures in inter partes review proceedings administered by the United States Patent and Trademark Office. The Court held that when the Patent Trial and Appeal Board institutes an inter partes review on a patent, it must decide the patentability of all claims the petitioner challenged, rather than just some claims. The decision affected litigation strategy for parties including technology firms, patent owners, and government agencies.

Background

SAS Institute Inc. v. Iancu arose from challenges to patents owned by ComplementSoft, with petitioner SAS Institute seeking inter partes review before the Patent Trial and Appeal Board, an adjudicative unit within the United States Patent and Trademark Office. The case involved statutory interpretation of the Leahy–Smith America Invents Act and its inter partes review provisions, which had been enacted by the United States Congress and signed into law by Barack Obama. The dispute implicated precedents from the Supreme Court of the United States, including prior decisions addressing administrative adjudication by the United States Court of Appeals for the Federal Circuit and the United States Court of Appeals for the D.C. Circuit. Parties referenced administrative law doctrines as shaped by justices such as Antonin Scalia, Ruth Bader Ginsburg, and Neil Gorsuch.

Procedural history

SAS Institute filed a petition asking the Patent Trial and Appeal Board to review all 16 claims of a patent held by ComplementSoft; the Board instituted review on only some claims, relying on its regulations. The Board issued a partial institution decision and subsequent final written decision that resolved fewer than all challenged claims. SAS appealed to the United States Court of Appeals for the Federal Circuit, which affirmed the Board's practice, prompting a petition for certiorari to the Supreme Court of the United States. The case drew amicus briefs from entities including Google, Microsoft, Apple Inc., Intel, IBM, Biogen, Pharmaceutical Research and Manufacturers of America, and the Electronic Frontier Foundation, as well as submissions from federal actors including the United States Solicitor General and the United States Department of Justice.

Supreme Court decision

The Supreme Court of the United States granted certiorari and heard oral argument with advocates drawn from major law firms and corporate counsel. In a 5–4 opinion authored by Neil Gorsuch, the Court reversed the United States Court of Appeals for the Federal Circuit and held that the Patent Trial and Appeal Board must issue a final written decision addressing the patentability of all claims the petitioner challenged in its inter partes review petition. The majority rejected the Board's regulatory practice and interpreted the statutory text of the Leahy–Smith America Invents Act to require complete resolution. The dissent, authored by Ruth Bader Ginsburg and joined by members including Stephen Breyer and Sonia Sotomayor, defended agency discretion and reliance on the Administrative Procedure Act. The decision remanded the case for further proceedings consistent with the Court's interpretation.

Legal reasoning and significance

The majority analyzed statutory text and construction, focusing on provisions specifying that the Director shall issue a decision "whether to institute an inter partes review" and that the Board "shall issue a final written decision with respect to the patentability of any patent claim challenged by the petitioner." The opinion engaged with interpretive tools used in cases such as Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. and Skidmore v. Swift & Co., and discussed precedents on agency adjudication like SEC v. Chenery Corp. (No. 2). The Court declined to defer to the United States Patent and Trademark Office's regulation under the Chevron framework, emphasizing clear statutory command and invoking textualist reasoning associated with jurists such as Antonin Scalia. The ruling affected doctrines on administrative discretion, adjudicatory completeness, and the balance between agency rulemaking powers recognized in cases such as Massachusetts v. EPA and PDR Network, LLC v. Carlton & Harris Chiropractic, Inc..

Subsequent developments and impact

Following the decision, the United States Patent and Trademark Office revised procedures to ensure that final written decisions in inter partes review address all challenged claims, affecting strategy at technology companies like Qualcomm, Oracle Corporation, Facebook, Inc., and Amazon (company), as well as biopharmaceutical firms such as Amgen and Pfizer. The ruling influenced subsequent Federal Circuit decisions and was cited in administrative law disputes in the United States Court of Appeals for the Federal Circuit and the United States Court of Appeals for the Second Circuit. Legislators in the United States Congress and commenters from entities including American Intellectual Property Law Association and Stanford University faculty debated statutory amendments. Legal scholarship in journals at institutions such as Harvard University, Yale University, Columbia University, and University of Chicago analyzed the case's implications for patent policy and administrative law. The decision also affected global intellectual property practice involving World Intellectual Property Organization processes and influenced patent enforcement strategies in forums including United States District Court for the District of Delaware and United States Court of Appeals for the Federal Circuit appeals.

Category:2018 in United States case law Category:United States Supreme Court cases Category:United States patent case law